November 19, 2008 |
Genentech Inc.'s Avastin, widely prescribed for colon cancer and some lung tumors, was linked to significantly higher rates of vein clotting in an analysis of earlier studies. Patients who got the drug were 33% more likely to have blood clots develop in their veins than those who didn't receive it, said researchers led by Shenhong Wu, a cancer specialist at Stony Brook University in Stony Brook, N.Y. Avastin, Genentech's top-selling drug, with $2.3 billion in 2007 U.S. sales, bears a warning for high risk of clots in arteries.
November 25, 2008 |
Genentech Inc. and Roche Holding's Avastin, in combination with the most commonly used chemotherapies, helped women with breast cancer live longer without their disease worsening, a finding that could bolster use of the medicine. Avastin, used as a first-line therapy and combined with either Switzerland-based Roche's Xeloda, a taxane drug such as paclitaxel or anthracycline, kept tumors in check in women with advanced breast cancer better than chemotherapy alone, the companies said.
February 27, 2004 |
Genentech Inc. on Thursday won Food and Drug Administration approval of its colon cancer drug Avastin, the first medication to shrink tumors by choking the blood vessels that feed them. Industry analysts said the drug could become a $2-billion-a-year product, which would make it the best-selling cancer medication to date. Wall Street drove Genentech's shares up 7%, adding $3.8 billion to the total market value of the South San Francisco company.
January 15, 2005 |
ImClone Systems Inc.'s Erbitux and Genentech Inc.'s Avastin medicines will be tested in a U.S. government-sponsored study comparing treatments for newly diagnosed colon cancer patients. Researchers scrapped an earlier study of chemotherapy and Erbitux because doctors were reluctant to use ImClone's drug instead of Avastin, which won approval after the Erbitux trial was designed. The new study will begin this year, Alan Venook, the doctor who is leading the research, said Friday.
March 16, 2005 |
Insurance giant Empire Blue Cross & Blue Shield said Tuesday that it would pay for use of Genentech Inc.'s Avastin in some lung cancer patients after a large clinical trial showed the drug prolonged the lives of such patients. Those who received Avastin plus chemotherapy in the clinical trial lived about 12.5 months, compared with 10.2 months in the chemotherapy-only group, according to the National Cancer Institute.
February 1, 2011 |
Avastin, a popular cancer drug that slows the growth of some types of tumors, may also be linked to an increased risk of death, new research suggests. A study published Tuesday in the Journal of the American Medical Assn. reviewed randomized controlled clinical trials from 1966 to 2010 with a total of 10,217 patients. FOR THE RECORD : An earlier version of this post said the FDA withdrew approval of Avastin for breast cancer patients in December. In fact, the FDA moved to begin the process of withdrawing approval.
July 2, 2011 |
Widespread screening with CT scans can detect lung cancer. Regular mammograms of all women 40 and older can find breast cancer. Avastin, at $8,000 a month, has helped some patients with advanced breast cancer. And the prostate cancer drug Provenge, at $93,000 per patient, can extend survival by about four months. Such were the headlines this week. But this made headlines too: Healthcare spending in the U.S. outpaces all other industrialized countries, amounting to 17.5% of our economic output.
November 26, 2003 |
Genentech Inc. said Tuesday that its Avastin cancer drug had failed to meet its primary goal of prolonging survival in a mid-stage trial of patients with metastatic colorectal cancer, but the company still expects U.S. approval of the drug next year. Genentech, which in September asked U.S.
January 30, 2012 |
In November, following an emotional public hearing some months earlier, the Food and Drug Administration withdrew approval for the cancer drug Avastin for patients with metastatic breast cancer - the late-stage, incurable form of the disease. The reason: emerging evidence that the drug does not prolong life and also that it's been linked to serious side effects. Now, confusingly, Avastin is back in the news again - this time, with positive results in two early trials of women with early-stage breast cancer whose tumors have not traveled beyond the breast or nearby lymph nodes.